Journal
INTERNATIONAL JOURNAL OF PHARMACEUTICS
Volume 636, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.ijpharm.2023.122809
Keywords
Intravitreal; Implant; Nanofiber; Bevacizumab; Dexamethasone; Drug delivery; Age-related macular degeneration
Categories
Ask authors/readers for more resources
Intravitreal injections are commonly used for drug delivery to the posterior segment of the eye, but their frequent administration leads to complications and poor adherence. Biodegradable nanofibers have the potential to regulate drug release and protect fragile bioactive drugs. Age-related macular degeneration is a leading cause of blindness and involves VEGF and inflammatory responses. In this study, we developed nanofiber-coated intravitreal implants for simultaneous delivery of dexamethasone and bevacizumab. The implants showed sustained drug release, reduction of vessels, and safety to the retina.
Intravitreal injections are the preferred choice for drug administration to the posterior segment of the eye. However, the required frequent injections may cause complications to the patient and low adherence to the treatment. Intravitreal implants are able to maintain therapeutic levels for a long period. Biodegradable nanofibers can modulate drug release and allow the incorporation of fragile bioactive drugs. Age-related macular degeneration is one of the world major causes of blindness and irreversible vision loss. It involves the interaction between VEGF and inflammatory cells. In this work we developed nanofiber-coated intravitreal implants containing dexamethasone and bevacizumab for simultaneously delivery of these drugs. The implant was successfully prepared and the efficiency of the coating process was confirmed by scanning electron microscopy. Around 68% of dexamethasone was released in 35 days and 88% of bevacizumab in 48hs. The formulation presented activity in the reduction of vessels and was safe to the retina. It was not observed any clinical or histopathological change, neither alteration in retina function or thickness by electroretinogram and optical coherence tomography during 28 days. The nanofiber-coated implants of dexamethasone and bevacizumab may be considered as a new delivery system that can be effective for the treatment of AMD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available